BALOXAVIR MARBOXIL

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C27H23F2N3O7S
Molecular Weight	571.549
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H][C@@]12COCCN1C(=O)C3=C(OCOC(=O)OC)C(=O)C=CN3N2[C@@H]4C5=C(SCC6=C4C=CC(F)=C6F)C=CC=C5

InChI

InChIKey=RZVPBGBYGMDSBG-GGAORHGYSA-N

InChI=1S/C27H23F2N3O7S/c1-36-27(35)39-14-38-25-19(33)8-9-31-24(25)26(34)30-10-11-37-12-21(30)32(31)23-15-6-7-18(28)22(29)17(15)13-40-20-5-3-2-4-16(20)23/h2-9,21,23H,10-14H2,1H3/t21-,23+/m1/s1

HIDE SMILES / InChI

Description
Sources: https://pubmed.ncbi.nlm.nih.gov/30316915 | https://clinicaltrials.gov/ct2/show/NCT04327791 |https://pubmed.ncbi.nlm.nih.gov/30316915/

Baloxavir or Baloxavir acid was developed by Shionogi and Co., Ltd as a selective inhibitor of the cap-dependent endonuclease (CEN) activity. CEN resides in the PA subunit of the influenza virus and mediates the critical "cap-snatching" step of viral RNA transcription. Thus Baloxavir can inhibit the influenza virus replication and now this drug is under investigation in clinical trial NCT04327791 (Combination Therapy With Baloxavir and Oseltamavir 1 for Hospitalized Patients With Influenza).

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Polymerase acidic protein 2 Target ID: CHEMBL2040544 Sources: https://pubmed.ncbi.nlm.nih.gov/30316915/	Inhibitor 8297		2.5 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Influenza 2 Sources: https://clinicaltrials.gov/ct2/show/NCT04327791	Curative		Phase II 1132

Sample Use Guides

In Vivo Use Guide

Baloxavir: 40 mg po once for wt < 80 kg OR 80 mg po once for wt >/= 80 kg

Route of Administration: Oral

In Vitro Use Guide

To assess the inhibitory effects of Baloxavir acid (BXA) on Cap-dependent endonuclease (CEN) and RNA-dependent RNA polymerase (RdRp) activities as well as the sequential reaction of CEN and RdRp (CEN/RdRp), recombinant 3Ptap derived from A/WSN/33 (H1N1) was subjected to a transcription assay. BXA inhibited CEN and CEN/RdRp activities with mean IC50 of 2.5 and 1.6 nM, respectively, while low potency (IC50 >40 nM) was observed against RdRp activity, suggesting that BXA selectively inhibits CEN activity.

Name

Type

Language

BALOXAVIR MARBOXIL

Official Name

English

(((12AR)-12-((11S)-7,8-DIFLUORO-6,11-DIHYDRODIBENZO(B,E)THIEPIN-11-YL)-6,8-DIOXO-3,4,6,8,12,12A-HEXAHYDRO-1H -(1,4)OXAZINO(3,4-C)PYRIDO(2,1-F)(1,2,4)TRIAZIN-7-YL)OXY)METHYL METHYLCARBONATE

Systematic Name

English

baloxavir marboxil [INN]

Common Name

English

CARBONIC ACID, (((12AR)-12-((11S)-7,8-DIFLUORO-6,11-DIHYDRODIBENZO(B,E)THIEPIN-11-YL)-3,4,6,8,12,12A-HEXAHYDRO-6,8-DIOXO-1H-(1,4)OXAZINO(3,4-C)PYRIDO(2,1-F)(1,2,4)TRIAZIN-7-YL)OXY)METHYL METHYL ESTER

Systematic Name

English

(((12AR)-12-((11S)-7,8-DIFLUORO-6,11-DIHYDRODIBENZO(B,E)THIEPIN-11-YL)-6,8-DIOXO-3,4,6,8,12,12AHEXAHYDRO-1H-(1,4)OXAZINO(3,4-C)PYRIDO(2,1-F)(1,2,4)TRIAZIN-7-YL)OXY)METHYL METHYL CARBONATE

Systematic Name

English

S-033188

Code

English

BALOXAVIR MARBOXIL [ORANGE BOOK]

Common Name

English

BALOXAVIR MARBOXIL [JAN]

Common Name

English

Baloxavir marboxil [WHO-DD]

Common Name

English

BALOXAVIR MARBOXIL [USAN]

Common Name

English

XOFLUZA

Brand Name

English

BALOXAVIR MARBOXIL [MI]

Common Name

English

Code System Code Type Description

SMS_ID

100000176055